Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus |
Sign Up Account Profile Log Out
Newsletters Morning Report 12:30 Report Evening Report Business Defense Health Care Technology Newsletter Energy & Environment Whole Hog Politics The Gavel The Movement
Technology Newsletter
NEWS Senate House Administration Courts Future America Media Campaign News Education In The Know Latino LGBTQ DC News Race & Politics State Watch Print Edition People in the News
POLICY Defense Health Care Energy & Environment Technology Transportation International Cybersecurity National Security Space Sustainability
BUSINESS Budget Taxes Personal Finance Lobbying
OPINION Columnists Congress Blog All Contributors Opinions – Campaign Opinions – Civil Rights Opinions – Criminal Justice Opinions – Cybersecurity Opinions – Education Opinions – Energy and Environment Opinions – Finance Opinions – Healthcare Opinions – Immigration Opinions – International Opinions – Judiciary Opinions – National Security Opinions – Technology Opinions – White House Submit Opinion Content
All Contributors Opinions – Campaign Opinions – Civil Rights Opinions – Criminal Justice Opinions – Cybersecurity Opinions – Education Opinions – Energy and Environment Opinions – Finance Opinions – Healthcare Opinions – Immigration Opinions – International Opinions – Judiciary Opinions – National Security Opinions – Technology Opinions – White House
Opinions – Civil Rights
Opinions – Criminal Justice
Opinions – Cybersecurity
Opinions – Energy and Environment
Opinions – Healthcare
Opinions – Immigration
Opinions – International
Opinions – National Security
Opinions – Technology
Opinions – White House
Submit Opinion Content
EVENTS Upcoming Events About
Sign Up Account Profile Log Out
Live updates: State of the Union
Content from Google Cloud
Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus Health Care | 1 minute ago
FedEx sues for Trump tariffs refund Business | 2 minutes ago
Supreme Court shields Postal Service from lawsuits over intentionally undelivered mail Court Battles | 4 minutes ago
De Niro: Trump ‘will never leave’ In The Know | 6 minutes ago
Opinion Trump’s moral flexibility on Iran isn’t an asset — it’s a vulnerability Opinions - International | 7 minutes ago
Wall Street Journal: ‘Smart play’ would have been for Trump to forgo, pause new tariffs Media | 16 minutes ago
Former FBI official: Patel Olympics appearance sends ‘horrible’ message to rank and file Administration | 24 minutes ago
Trump says State of the Union will be ‘long speech’: What’s the record? Administration | 25 minutes ago
Novo Nordisk slashing prices for weight-loss and diabetes drugs Ozempic, Wegovy and Rybelsus
Novo Nordisk announced Tuesday it will be slashing the list price of its blockbuster GLP-1 medications, Ozempic, Wegovy and Rybelsus, by up to 50 percent beginning next year.
Starting on Jan. 1, 2027, the list price for Wegovy, Ozempic and Rybelsus, Novo’s semaglutide products, will be $675 across the board in the U.S.
This reduction represents a 50 percent cut for oral and injectable Wegovy, with current list prices of $1,349.02. It’s a 34 percent cut for Ozempic and Ryeblsus, which are both currently priced at $1,027.51.
“Lowering the list price of Wegovy® and Ozempic® is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States. Private and public payers, as well as patients, want access and have been calling for lower list prices,” Jamey Millar, executive vice president of Novo Nordisk’s U.S. operation, said in a statement.
Due to high demand and interest, Novo has sought avenues to make its blockbuster line of semglutide products available at lower prices, launching direct-to-consumer portals and collaborations with telemedicine platforms to offer the drug without the autoinjector.
Federal government pressures to lower prices have also come into play.
The Centers for Medicare and Medicaid Services (CMS) selected semaglutide for Medicare negotiations last year. In November, CMS unveiled it had negotiated a a 71 percent discount on a 30-day supply of semaglutide for Medicare, going from $959 to $274. These prices are scheduled to go into effect at the start of 2027.
The Trump administration additionally pushed several companies, including Novo, to enter into “Most Favored Nation” (MFN) drug pricing agreements last year, with manufacturers agreeing to sell their GLP-1 injectables for a monthly starting price starting of $245 for people on Medicare and Medicaid.
While President Trump’s MFN policy called for drug companies to “offer American consumers the most-favored-nation lowest price,” a spokesperson for Novo Nordisk told The Hill that this slash in costs is unrelated to the company’s MFN agreement with the administration.
“Private and public payers, as well as patients, want access and have been calling for lower list prices. This action answers that call and removes cost barriers so the value of semaglutide can be realized by more patients. It is intended to connect more people with our innovative medicines specifically those whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs,” the Novo spokesperson said.
Copyright 2026 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
More Health Care News
Gorsuch takes aim at fellow Supreme Court justices in tariff decision
Hegseth says he’ll order random pizzas to throw off monitoring app
France bars US ambassador Kushner from meeting government officials
White House plays hardball with Democrats over DHS shutdown
Democratic leaders scrambling to prevent repeat of last year’s rowdy State of ...
Here’s how Trump’s polling has changed since last year
Senate Democrat: Trump has ‘no intention of following’ Constitution on ...
GOP set for internal battle over Supreme Court tariff ruling
Republicans eye opening for DHS deal this week as Democrats double down
Democrats prepare to protest Trump State of the Union: What to know
Former FBI official: Patel Olympics appearance sends ‘horrible’ message to ...
Trump puts Iran’s leader in double bind: Capitulation or risk of war
GOP members call on Tony Gonzales to resign over alleged affair
Senate Democrats unveil Trump tariffs refund legislation
State Department receives hundreds of calls on 24/7 crisis hotline for US ...
Key things to watch for in Pennsylvania, Maine special elections
Trump says State of the Union will be ‘long speech’: What’s the record?
Texas GOP Senate candidate: ‘It’s time for the next generation of American ...
The Hill Podcasts – Morning Report
2024 Election Results
2024 Election Forecast
Regulation - Administration
Energy & Environment Video Clips
Health Care Video Clips
Technology Video Clips
Transportation Video Clips
International Video Clips
Cybersecurity Video Clips
National Security Video Clips
Contributors to The Hill
Submit Opinion Content
PRIVACY POLICY 09/30/2025
Advertise with Nexstar
Journalistic Integrity
THE HILL 400 N CAPITOL STREET NW, SUITE 650 WASHINGTON DC 20002
© 1998 - 2026 Nexstar Media Inc. | All Rights Reserved.
Provided by Nexstar Media Group, Inc.
Sign in to create a free account. No password needed.
By clicking on any of the sign up options below, you confirm that you have read and agree to our Terms of Use, which includes a jury trial waiver and class action waiver, and that you have read our Privacy Policy detailing our collection, use and sharing of your personal information.
By clicking on any of the sign up options below, you confirm that you have read and agree to our Terms of Use, which includes a jury trial waiver and class action waiver, and that you have read our Privacy Policy detailing our collection, use and sharing of your personal information.
The Hill is provided by Nexstar Media Group, Inc., and uses the My Nexstar sign-in, which works across our media network.
Learn more at nexstar.tv/privacy-policy.
The Hill is provided by Nexstar Media Group, Inc., and uses the My Nexstar sign-in, which works across our media network.
Nexstar Media Group, Inc. is a leading, diversified media company that produces and distributes engaging local and national news, sports, and entertainment content across its television and digital platforms. The My Nexstar sign-in works across the Nexstar network—including The CW, NewsNation, The Hill, and more. Learn more at nexstar.tv/privacy-policy.
Provided by Nexstar Media Group, Inc.
Check your email inbox
Provided by Nexstar Media Group, Inc.
Thanks for registering!
Provided by Nexstar Media Group, Inc.
Are you sure you want to log out?